{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:06:22Z","timestamp":1792173982731,"version":"4.4.0"},"reference-count":46,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T00:00:00Z","timestamp":1673827200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Annals of Medicine"],"published-print":{"date-parts":[[2023,12,12]]},"DOI":"10.1080\/07853890.2022.2164611","type":"journal-article","created":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T09:34:47Z","timestamp":1673861687000},"page":"348-360","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":9,"title":["Efficacy and safety of combination therapies vs monotherapy of hypomethylating agents in accelerated or blast phase of Philadelphia negative myeloproliferative neoplasms: a systematic review and meta-analysis"],"prefix":"10.1080","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7096-1056","authenticated-orcid":false,"given":"Jia","family":"Chen","sequence":"first","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China"},{"name":"Tianjin Institutes of Health Science, Tianjin, China"},{"name":"MDS and MPN Centre, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kefei","family":"Wang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China"},{"name":"Tianjin Institutes of Health Science, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijian","family":"Xiao","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China"},{"name":"Tianjin Institutes of Health Science, Tianjin, China"},{"name":"MDS and MPN Centre, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zefeng","family":"Xu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China"},{"name":"Tianjin Institutes of Health Science, Tianjin, China"},{"name":"MDS and MPN Centre, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,1,16]]},"reference":[{"key":"e_1_3_5_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-643544"},{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2017.05.010"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-02-138230"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2006.12.002"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2737"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2016.09.017"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019001084"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020004856"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-08-733196"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1159\/000506146"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-274811"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018019661"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26186"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2700"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1445-2197.2003.02748.x"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2012.08.013"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.04.036"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.4262.4262"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.1124.1124"},{"issue":"1","key":"e_1_3_5_21_1","first-page":"1379","article-title":"The combination of ruxolitinib (RUX) with decitabine (DAC) in patients (pts) with post-myeloproliferative neoplasm acute myeloid leukemia (post-MPN AML): interim report of a phase I\/II trial [abstract]","volume":"130","author":"Assi R","year":"2017","unstructured":"Assi R, Bose P, Verstovsek S, et\u00a0al. The combination of ruxolitinib (RUX) with decitabine (DAC) in patients (pts) with post-myeloproliferative neoplasm acute myeloid leukemia (post-MPN AML): interim report of a phase I\/II trial [abstract]. Blood. 2017;130(Suppl_1):1379.","journal-title":"Blood"},{"issue":"1","key":"e_1_3_5_22_1","first-page":"1649","article-title":"A phase Ib study to assess the safety and tolerability of ruxolitinib in combination with azacitidine in patients with advanced phase myeloproliferative neoplasms (MPN), including myelodysplastic syndromes (MDS) or ACUTE MYELOID LEUKAEMIA (AML) arising from MPN (the bloodwise\/TAP PHAZAR study on behalf of the UK MPN CSG) [conference abstract]","volume":"130","author":"Drummond MW","year":"2017","unstructured":"Drummond MW, Harrison CN, Vicente SM, et\u00a0al. A phase Ib study to assess the safety and tolerability of ruxolitinib in combination with azacitidine in patients with advanced phase myeloproliferative neoplasms (MPN), including myelodysplastic syndromes (MDS) or ACUTE MYELOID LEUKAEMIA (AML) arising from MPN (the bloodwise\/TAP PHAZAR study on behalf of the UK MPN CSG) [conference abstract]. Blood. 2017;130(Suppl_1):1649.","journal-title":"Blood"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2018.05.004"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0778-0"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17084"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002119"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2020.106456"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003934"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26381"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-151352"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.3164.3164"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.32.15_suppl.e18006"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2015.06.001"},{"issue":"21","key":"e_1_3_5_34_1","first-page":"5270","article-title":"Azacitidine in the treatment of PH-myeloproliferative neoplasms in blastic phase - the experience of Gruppo Laziale for the study of PH-SMPC [abstract]","volume":"122","author":"Andriani A","year":"2016","unstructured":"Andriani A, Latagliata R, Voso MT, et\u00a0al. Azacitidine in the treatment of PH-myeloproliferative neoplasms in blastic phase - the experience of Gruppo Laziale for the study of PH-SMPC [abstract]. Blood. 2016;122(21):5270.","journal-title":"Blood"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.1940.1940"},{"issue":"1","key":"e_1_3_5_36_1","first-page":"1635","article-title":"Treatment of myeloproliferative neoplasms in blastic phase with azacytidine. Clinical results and identification of prognostic factors [abstract]","volume":"130","author":"Andriani A","year":"2017","unstructured":"Andriani A, Montanaro M, Breccia M, et\u00a0al. Treatment of myeloproliferative neoplasms in blastic phase with azacytidine. Clinical results and identification of prognostic factors [abstract]. Blood. 2017;130(Suppl_1):1635.","journal-title":"Blood"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.15988"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24973"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2018.1441408"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0019-y"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2635"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-134701"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01600"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-08-868752"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.701690"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26061"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26190"}],"container-title":["Annals of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/07853890.2022.2164611","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T19:20:19Z","timestamp":1705432819000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/07853890.2022.2164611"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,16]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,12,12]]}},"alternative-id":["10.1080\/07853890.2022.2164611"],"URL":"https:\/\/doi.org\/10.1080\/07853890.2022.2164611","relation":{},"ISSN":["0785-3890","1365-2060"],"issn-type":[{"value":"0785-3890","type":"print"},{"value":"1365-2060","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,16]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iann20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iann20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-08-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}